A Phase 1, Randomized, Double Blind, Placebo Controlled, Dose Escalation, and Bioavailability Study Evaluating the Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Subjects With Cystic Fibrosis

Trial Profile

A Phase 1, Randomized, Double Blind, Placebo Controlled, Dose Escalation, and Bioavailability Study Evaluating the Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Subjects With Cystic Fibrosis

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Sep 2017

At a glance

  • Drugs VX 659 (Primary) ; Ivacaftor; Tezacaftor
  • Indications Cystic fibrosis
  • Focus Adverse reactions
  • Sponsors Vertex Pharmaceuticals
  • Most Recent Events

    • 01 Sep 2017 Status changed from recruiting to completed.
    • 22 Jul 2017 There is a discrepancy in phase of the study. Accordinf to NCT it is phase 1 where as MR and conmpany website states it as phase 2. Presently retained phase as per NCT (phase 1), please update the same on receiving further information.
    • 08 Jan 2017 According to Vertex Pharmaceuticals media release, dosing in this trial is planned in the first half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top